News & Events

HighTide Therapeutics Appoints Edmund Sim as Chief Financial Officer

February 01, 2023

ROCKVILLE, MD and SHENZHEN, CHINA, February 01, 2023 — HighTide Therapeutics, Inc. (“HighTide”), a clinical-stage biopharmaceutical company developing multifunctional therapies for metabolic and digestive diseases, today announced the appointment of Edmund Sim as Chief Financial Officer (CFO). Mr. Sim will report to Dr. Liping Liu, Founder and CEO of HighTide.

Mr. Sim has been in the field of investment and financing for over 20 years in US and China. Prior to HighTide, he worked in a contract research organization and led the international business development and fundraising exercise. Mr. Sim has extensive capital markets experience with global investment banks in US and China.

At HighTide, he will be responsible for the group financing and capital market activities. In addition, he will play a key role in global business strategy and corporate development.

“We are very pleased to welcome Edmund to the HighTide executive team. Edmund’s extensive experience in capital markets and clinical research organization adds great values to our team. He will play a central role in financing, capital market activities, and overall business and corporate development,” said Dr. Liping Liu, Founder and CEO of HighTide.

“I am excited about joining the experienced and dedicated HighTide team,” said Mr. Sim. “Metabolic and digestive diseases are one of key areas for development in future. HighTide recently completed the US$107M financing which will expedite the clinical studies of T2DM, NASH, SHTG and PSC around the globe. Healthy and solid financial support will ensure an undisruptive clinical development to bring solutions soonest to patients."

During his tenure, Mr. Sim joined Vitasky Research as the general manager of the International Business and group VP which completed numerous rounds of pre-IPO financings and set up overseas laboratories in Melbourne, Australia. Prior, he worked for China Merchant Securities International, BofA Securities, Goldman Sachs, Citigroup, Bank of China International who manage 100 plus employees and successfully completed more than 130 IPO projects globally. Mr. Sim holds a Bachelor of Business Degree in Queensland University of Technology, Master of Science in Financial Management in University of London and CPA qualification in Hong Kong.

About HighTide
HighTide Therapeutics Inc. is a globally integrated biopharmaceutical company focusing on the discovery and development of first-in-class multifunctional therapies with poly-indications across metabolic and digestive diseases with significant unmet medical needs.  The company is developing multiple clinical assets, including therapy for nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2DM), severe hypertriglyceridemia (SHTG), primary sclerosing cholangitis (PSC) and primary biliary cholangitis (PBC).  HTD1801, the company’s lead drug candidate, received Fast Track designation from the U.S. FDA for both NASH and PSC, as well as Orphan Drug designation for PSC.  In China, HTD1801 has been included in the National Major New Drug Innovation Program under the 13th Five-Year Plan for Major Technology Project.

For more information, please visit, Contact:

Share on WeChat circle of friends ×
Open WeChat
Use Scan to share web pages with your friends.


We will contact you as soon as possible

HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm HighTide,君圣泰,君圣泰医药,非酒精性脂肪性肝炎,nash,2型糖尿病,t2dm

© 2024 HighTide Therapeutics, Inc.

Legal StatementPrivacy PolicyCookie Policy


Follow Us

© 2024 HighTide Therapeutics, Inc.